XenovaBio experience

Experience
Xenova Biomanufacturing has an impressive track record of process innovation in the development, manufacture and quality control of products for clinical trials, across a wide range of product types, including recombinant proteins, conjugated vaccines, viruses and gene therapy vectors.

	Client Testimonials.

	Phico Therapeutics (2006 _ )
	The consultancy facility at Xenova is available to help wherever we have expertise to help with the complexities of processes, assays, manufacturing and regulations. Phico have made use of this in bringing their MRSA antibacterial to clinical trials manufacture. Heather Fairhead, CEO at Phico, said “We have been able to tap into all of Xenova Bio’s expertise and that has been invaluable for our project. We have had access to expert advice on the manufacturing process and the assays, but also on regulatory aspects.”


	Protherics (2006 _ )
	Protherics signed a contract with Xenova Bio in 2006 for the development of an existing process and for the manufacture of Phase II clinical supplies for its Angiotensin Therapeutic Vaccine, an angiotensin conjugate vaccine. Karen Duckworth, manager of contract development manufacture at Protherics, explained “Xenova has a lot of experience with conjugate vaccine products and they understood exactly the process requirements.” Xenova Bio has begun the optimisation of the Protherics’ Phase I process and is on schedule to implement the process for Phase II manufacture in 2007. It is expected that the Phase II process will be scaleable and ready for commercial production in the future.

	this page is under continuing construction